Custom AAV production so the batch can be dosed: capsid, purification and titre truth

Specifying the batch

1. Choose the serotype from the target, then check manufacture. Tropism and immune exposure differ between serotypes, and so does how easily each is produced and purified. A serotype chosen purely on published tropism can be a difficult manufacturing programme, and that is worth knowing before the construct is fixed.
2. Name every titre method in the contract. Genome titre, capsid titre and infectious titre differ by large factors and each depends on its assay design and standard. A batch specification that says a number without a method has specified nothing.
3. Set an empty and partial capsid limit. Capsids carrying no genome or a truncated one contribute to the immune load and not to the effect. Separating them is a real unit operation with a real yield cost, and the limit belongs in the specification rather than in the report.
4. Build the purification around what the dose requires. Affinity capture concentrates the vector; it does not separate full from empty. Density or ion exchange based polishing is what does that, and omitting it is the commonest gap between a research batch and a usable one.
5. Agree the release panel before manufacture. Identity, genome titre, capsid content, purity, residual host protein and DNA, residual plasmid, replication competent vector where applicable, endotoxin and sterility. Agreeing it afterwards means testing retained samples for methods that were not ready.
6. Plan the analytics with the same lead time as the batch. Assays that are not qualified when the batch is released delay everything. Analytical development belongs on the same timeline as process development, not behind it.

Titre is a contract term, not a measurement

Because the number depends so heavily on method, the useful approach is to treat titre as something negotiated and defined rather than reported. Name the assay, the standard, the amplicon position where relevant, and the acceptance range, and require the same method for every batch.

Then have one batch measured independently. A single cross check early tells you whether your partner's number and the rest of the world's number are the same size, and it is far cheaper than discovering a systematic offset during a study.

Plasmid supply is the quiet constraint

Triple transfection processes consume large quantities of graded plasmid, and plasmid lead times at that grade are long. Programmes routinely lose weeks because the vector slot was booked before the plasmid was ordered.

Sequence the ordering: plasmid grade decided, plasmid ordered, then the manufacturing slot. Doing it the other way round produces an idle suite and an invoice.

AAV analytics, and the three numbers a batch is judged on

Three measurements decide whether a preparation is usable and they are often reported as one: the physical particle titre, the genome titre, and the ratio between them, which is the share of capsids carrying a genome. A high physical titre with a poor ratio is mostly empty capsid, which competes for uptake and contributes to the dose without contributing to the effect.

Beyond those, the batch owes identity of the genome, residual host cell DNA and plasmid, and an infectivity or potency readout in a cell model. Ask which method produced each number, because titres from different methods are not comparable and a supplier switching method mid programme changes the dose without changing the process.

aav quantification, and which titre a number refers to

An AAV titre is meaningless without the method beside it. Genome copies per millilitre, read by qPCR or digital PCR against a linearised standard, counts packaged genomes and is what most quotes state. Capsid titre by ELISA counts particles whether they carry a genome or not, and the ratio between the two is the empty to full figure a programme is judged on. Infectious titre, read on a permissive cell line, is the number that predicts what a transduction will do. Ask which method produced the number, which standard it was calibrated against, and what the assay variability is.

An aav cdmo, and what to ask before the slot

An AAV CDMO is chosen on the platform it already runs, not on the capacity chart. Ask which production system the suite is set up for, adherent or suspension, transient transfection or a producer line, and what the yield per litre and the full to empty ratio have been on programmes like yours. Then ask about analytics, because release for a viral vector is largely an analytical problem: titre by digital PCR, capsid content, residual host cell DNA and plasmid, and potency. Slot availability and the technology transfer package are the commercial questions once the platform fits.

aav plasmids, and the aav plasmid set a prep needs

A triple transfection needs three plasmids and each is a separate specification: the transfer plasmid carrying your transgene between the inverted terminal repeats, the rep-cap plasmid supplying the serotype, and the helper plasmid supplying the adenoviral functions. Ratios are tuned per platform and the ITR plasmid is the one to sequence carefully, since the repeats are unstable in propagation and a truncated ITR gives packaging failure that looks like a transfection problem. For anything heading toward the clinic all three are bought at a grade with a batch record, which is where most of the cost sits.

aav viral vector manufacturing, and the platform behind a quote

A manufacturing quote is a platform decision first. Adherent HEK293 in stacks is cheap to start and does not scale past a point; suspension culture in single use bioreactors scales and costs more to set up; a stable producer line removes the plasmids and takes months to build; and the baculovirus insect cell route trades a different set of impurities for high volumetric yield. Each carries its own purification train and its own residual profile, so the analytics and the fill are quoted against the platform rather than the dose.

viral vector services, and what to specify

Buying vector rather than making it is usually right below a certain scale, and the specification is what makes quotes comparable: serotype or pseudotype, the transgene cassette with its sequence, the amount in genome copies or transducing units rather than millilitres, the purity and empty-to-full expectation, the buffer and the fill format, and the testing, titre, sterility, mycoplasma, endotoxin, residual DNA. Ask for a certificate of analysis from a previous batch, since the panel it carries tells you more about a provider than a capability list does.

Common questions

Why do two laboratories report different titres for one batch?

Different assay designs, different standards and sometimes different primer positions within the genome. It is the norm rather than the exception, which is why the method belongs in the specification and an independent cross check is worth running once.

Do empty capsids matter?

Yes. They add to the total capsid load without contributing effect, which affects the immune response and the interpretation of dose. Regulators expect the fraction to be measured and controlled, not merely reported.

Is affinity purification enough, or do I need full AAV purification?

For research use often yes. For anything dosed, no, because affinity resins bind the capsid regardless of what is inside it. A polishing step that separates by density or charge is required to control the full fraction.

What lead time should be assumed?

Longer than the manufacturing slot suggests, because plasmid supply, analytical qualification and release testing all sit around it. Booking a slot without those in place produces an expensive wait.

Browse by service class

• Compare Gene synthesis on advertised prices